










































HspB5 Activates a Neuroprotective Glial Cell Response in
Experimental Tauopathy
Citation for published version:
Hampton, DW, Amor, S, Story, D, Torvell, M, Bsibsi, M, Van Noort, JM & Chandran, S 2020, 'HspB5
Activates a Neuroprotective Glial Cell Response in Experimental Tauopathy', Frontiers in Neuroscience, vol.
14. https://doi.org/10.3389/fnins.2020.00574
Digital Object Identifier (DOI):
10.3389/fnins.2020.00574
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 31. Jul. 2020
fnins-14-00574 June 9, 2020 Time: 20:58 # 1
BRIEF RESEARCH REPORT
















This article was submitted to
Neurodegeneration,
a section of the journal
Frontiers in Neuroscience
Received: 26 March 2020
Accepted: 11 May 2020
Published: 11 June 2020
Citation:
Hampton DW, Amor S, Story D,
Torvell M, Bsibsi M, van Noort JM and
Chandran S (2020) HspB5 Activates




HspB5 Activates a Neuroprotective
Glial Cell Response in Experimental
Tauopathy
David W. Hampton1* , Sandra Amor2, David Story1, Megan Torvell3, Malika Bsibsi4,
Johannes M. van Noort4 and Siddarthan Chandran1,5
1 Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, United Kingdom, 2 Department of Pathology, VU
University Medical Center, Amsterdam, Netherlands, 3 UK Dementia Research Institute, Cardiff University, Cardiff,
United Kingdom, 4 Delta Crystallon, Leiden, Netherlands, 5 UK Dementia Research Institute, Edinburgh University, Edinburgh,
United Kingdom
Progressive neuronal death during tauopathies is associated with aggregation of
modified, truncated or mutant forms of tau protein. Such aggregates are neurotoxic,
promote spreading of tau aggregation, and trigger release of pro-inflammatory factors
by glial cells. Counteracting such pathogenic effects of tau by simultaneously inhibiting
protein aggregation as well as pro-inflammatory glial cell responses would be of
significant therapeutic interest. Here, we examined the use of the small heat-shock
protein HspB5 for this purpose. As a molecular chaperone, HspB5 counteracts
aggregation of a wide range of abnormal proteins. As a TLR2 agonist, it selectively
activates protective responses by CD14-expressing myeloid cells including microglia.
We show that intracerebral infusion of HspB5 in transgenic mice with selective neuronal
expression of mutant human P301S tau has significant neuroprotective effects in the
superficial, frontal cortical layers. Underlying these effects at least in part, HspB5
induces several potent neuroprotective mediators in both astrocytes and microglia
including neurotrophic factors and increased potential for removal of glutamate.
Together, these findings highlight the potentially broad therapeutic potential of HspB5
in neurodegenerative proteinopathies.
Keywords: heat shock protein, astrocytes, microglia, tau, neurodegeneration, neuroprotection
INTRODUCTION
Accumulation of hyperphosphorylated and aggregated tau is a hallmark of neurodegenerative
diseases such as Alzheimer’s disease and other tauopathies (Spillantini and Goedert, 2013).
Mutations in tau cause inherited frontotemporal dementia (FTD) establishing that abnormality
of tau protein alone is sufficient to cause neurodegeneration (Lee et al., 2001). Overexpression
of human mutant P301S tau in mice under a neuron-specific promoter has previously been
shown to recapitulate the core features of tauopathies including progressive neuronal loss, a
neuroinflammatory response and accumulation of hyperphosphorylated tau, thus making this
model suitable for the evaluation of putative therapeutic strategies (Bellucci et al., 2004, 2011; Sasaki
et al., 2008; Hampton et al., 2010; Jucker and Walker, 2011; Holmes et al., 2014; Torvell et al., 2019).
As a molecular chaperone, HspB5 counteracts aggregation, eliminates neurotoxicity of a wide
range of different abnormal protein aggregates (Waudby et al., 2010; Mannini et al., 2012;
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Yerbury et al., 2013; Hochberg et al., 2014) and inhibits
hyperphosphorylation of tau and its aggregation into oligomers
and insoluble fibers in vivo (Dabir et al., 2004; Björkdahl
et al., 2008). In experimental neurodegenerative diseases,
e.g., Alzheimer’s and Parkinson’s, increased expression of
HspB5 in neural cells correlates with reduced damage and
improved functional recovery (Ojha et al., 2011; Marino
et al., 2015). Evidence from the neuroinflammation field has
revealed the additional ability of HspB5 to activate a TLR2-
mediated neuroprotective and anti-inflammatory response
in CD14-expressing myeloid cells including microglia (van
Noort et al., 2010, 2013; Bsibsi et al., 2013, 2014). In line with
these biological activities, administration of HspB5 ameliorates
neuroinflammation, stroke, spinal cord injury, and optic nerve
damage in experimental models (Ousman et al., 2007; Arac et al.,
2011; Pangratz-Fuehrer et al., 2011; Klopstein et al., 2012; Wu
et al., 2014), and symptoms of multiple sclerosis in humans
(van Noort et al., 2015). In the present study, we examined its
effects in an experimental model of human tauopathy. Upon
intracerebral infusion in P301S mice, HspB5 led to a significant
neuroprotective effect, which was associated with protective
responses by both microglia and astrocytes.
RESULTS AND DISCUSSION
HspB5 Is Neuroprotective in an in vivo
Model of Tauopathy
Here, we show that implantation of a cannula (at 8 weeks of
age, location and area analyzed in the superficial motor cortex
shown in Figures 1A–C) and infusing PBS or myoglobin for
4 weeks did not alter the loss of NeuN+ or GABAergic+ neurons
(Figures 1I–R). This is important as we have reported previously
(Hampton et al., 2010; Torvell et al., 2019) that numbers of
NeuN+ and GABA+ neurons in the superficial frontal cortex are
significantly decreased in 12-week old P301S mice as compared
to 8-week P301S mice or healthy, 12-week old C57/BL6 mice.
Thus validating this observation again here we show that NeuN+
(969.7 ± 211.3 for C57/BL6 compared to 285.6 ± 71.5 in P301S)
and GABA+ (482.6± 34.3 for C57/BL6 compared to 83.3± 23.5
in P301S) neurons are lost in this superficial frontal motor cortex
by 12 weeks of age (Figures 1D–H). Also numbers of GFAP+
reactive astrocytes are increased, thus further verifying this
age-dependent model of tau-driven, superficial frontal cortical
neuronal loss. To normalize data a ratio of the contralateral,
non-infused hemisphere to infused hemisphere was generated.
This revealed a ratio of 1.3 ± 0.5 and 1.2 ± 0.3 for PBS and
myoglobin infusion respectively thus confirming that control
infusions (be it either PBS or myoglobin) had no impact on
neuronal survival (Figures 1M,R). In contrast, neuronal density
ratio was significantly increased following 4-week infusion of
HspB5 (2.4 ± 0.4 for NeuN+; 2.6 ± 0.3 GABA+ neurons)
(Figures 1L,M,Q,R), similar to 12-week old C57/BL6 control
mice, or P301S mice prior to neuronal loss. Thus, infusion with
HspB5 is neuroprotective, significantly preventing neuronal loss
in the outer cortical layers.
HspB5 and Glial Activation in an in vivo
Model of Tauopathy
Next, the impact of the infusions on numbers of Iba-1+microglia
and GFAP+ reactive astrocytes were examined. As shown in
Figures 2A–J, infusions of PBS or myoglobin or HspB5 all
induced a significant increase in the number of reactive glial
cells, with no differences between each infused group except
when compared to normal 12 weeks old P301S mice. Thus PBS
(2.2 ± 0.2 Iba1; 2.2 ± 0.5 GFAP), myoglobin (1.9 ± 0.3 Iba1 and
1.7 ± 0.3 GFAP) and HspB5 (2.2 ± 0.3 Iba1; 2.4 ± 0.4 GFAP)
all increased these reactive glial markers to a similar extent.
Therefore it was not an increase in the numbers of reactive glia
that was responsible for the observed neuroprotective effect of
HspB5 only, leading us to further examine the impact of HspB5
on glial phenotype.
HspB5 Induces a Secondary
Neuroprotective Response in Astrocytes
Previously we have shown that transplantation of astrocytes
can be neuroprotective in the P301S mouse (Hampton et al.,
2010). Given that activation of innate cellular responses by
HspB5 is mediated via TLR2, with CD14 as an essential co-
receptor (van Noort et al., 2010; Bsibsi et al., 2013, 2014),
which are absent on astrocytes, any direct activation of astrocytes
by HspB5 would be unexpected. Indeed, investigations of
treatment of cultured human astrocytes with HspB5 showed
no significant increase in neurotrophic factors including NGF
and BDNF previously shown to be increased following astrocyte
transplantation into the P301S mice (Hampton et al., 2010)
(Figures 3A–C). However, exposure to HspB5 accompanied by
soluble factors released by HspB5-activated human microglia did
trigger astrocyte activation of BDNF, NGF, and LIF (Figures 3A–
C) and resulted in significantly increased production of EAAT2
(Figure 3D). EAAT2, the human equivalent of GLT-1, is an
astrocyte specific glutamate reuptake transporter that is critical
to regulating glutamate homeostasis at the synaptic cleft (Soni
et al., 2014). Expression of EAAT2 on HspB5-activated astrocytes
was also confirmed by immunocytochemical staining (Figure 3E)
and quantification of EAAT2 transcripts showed an 80-fold
increase (Figure 3F). Individual pro-inflammatory mediators
(including TNFα or interleukin-10) alone or culture medium
from unstimulated microglia did not increase EAAT2 production
on astrocytes. Thus, the combination of HspB5 with products
secreted by HspB5-activated microglia produced this significant
induction in astrocytes of EAAT2 and other neuroprotective
factors (Figures 3A–F). In support of these in vitro findings,
analysis of HspB5-treated P301S mouse brains revealed a
significant increase in GLT-1 positive/GFAP positive astrocytes
(364± 32.8 per mm2) compared to myoglobin (221.9± 33.1 per
mm2) or PBS (229.3± 51.3) not only in P301S mice (Figures 3G–
O) but also C57/BL6 control animals (Figures 3P–V).
Our present findings demonstrate that the significant
neuroprotective effects of HspB5 in the P301S model of tauopathy
are associated with activation of local glial cells. Previous data
have already documented induction in microglia of several anti-
inflammatory and neuroprotective mediators by HspB5 (van
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FIGURE 1 | Intracerebral infusion of HspB5 is neuroprotective in P301S mice. Overview images (A–C) to show where canula were inserted (co-ordinates based on
Bregma detailed in methods) as well as area of analysis. Sagittal image from a C57/BL6 stained with cresyl violet providing an overview of infusion site based on
cannulas being inserted through the skull to a depth of 0.5 mm to touch the surface of the cortex, 0.75 mm lateral from the midline and 1.2 mm forward from
bregma, marked by the thick dotted black line with the box highlighting area for analysis (A), scale bar = 2 mm. Coronal image highlighting a potential area of
analysis in the dotted box, scale bar = 500 µm with (C) showing this area zoomed in and the dotted box in (C) showing the representative area where all following
analysis would be performed in, scale bar = 100 µm. P301S (n = 4) mice compared to age-matched C57/BL6 (n = 7) control mice (D–H). Scale Bars = 100 µm for
(D–G) and quantification of both NeuN and GABAergic interneurons within this superficial region (H) (asterisks signifying P < 0.05, one way ANOVA, Tukey test) in
the P301S mice when compared to the C57/BL6 mice. P301S mice (at 8 weeks old) were either not treated (I,N, n = 4), or infused with PBS (J,O, n = 5) myoglobin
(K,P, n = 7), or HspB5 (L,Q, n = 10) in a continuous manner using osmotic mini-pumps connected to a canula overlaying the superficial surface of the cortex for
4 weeks. At 12 weeks of age, the superficial cortex was examined for viable neurons expressing either NeuN (I–M) or GABA (N–R; arrows highlight GABA+
neurons). (M,R) Show quantification of the numbers of viable neurons relative to the untreated contralateral hemisphere, with the dotted line signifying normal
12 weeks old P301S mice(asterisk signifying P < 0.01, one way ANOVA, Tukey test). All scale bars are shown for grouped images therefore panels (I–L,N–Q) the
scale is the same with a representative bar shown in (I) or (N) = 100 µm.
Noort et al., 2010; Bsibsi et al., 2013, 2014). Our current findings
extend this by revealing that astrocytes can also respond to HspB5
in a neuroprotective manner, but only when simultaneously
exposed to the secreted products of HspB5-activated microglia
as cofactors. Together, these data provide the first experimental
evidence of a neuroprotective effect of HspB5 in a model of
inherited neurodegeneration due to mutant tau.
MATERIALS AND METHODS
Treatment of P301S Mice
P301S transgenic mice (female, 8 weeks age) were anesthetized
and positioned into a stereotaxic frame (David Kopf Instruments,
Tujunga, CA, United States). Alzet micro-osmotic pumps model
1004 (Durect Corporation, Cupertino, CA, United States) were
filled with 100 µl of a sterile solution of PBS containing
12.5 mg/mL recombinant human HspB5 (Delta Crystallon,
Leiden, NL), 12.5 mg/mL myoglobin (M5696; Sigma Aldrich, St.
Louis, MO, United States), or PBS-only resulting in infusions
of an average of 33 µg of total protein, within roughly 3 µl of
solution per day at a rate of 0.1 µl per hour, via a cannula (Alzet
brain infusion kit 3) positioned approximately 0.5 mm deep,
resting onto the surface of the cortex 0.75 mm laterally from the
midline and 1.2 mm forward from bregma as shown in Figure 1.
This area was chosen for the infusions as we have previously
shown significant neuronal loss within this region of the motor
cortex at 12 weeks of age in P301S mice.
Animals were euthanized 4 weeks post-cannulation at
12 weeks of age, perfused with 4% paraformaldehyde in
PBS. Brains were removed, post-fixed in 4% paraformaldehyde
overnight, cryoprotected in 25% sucrose solution, and frozen in
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FIGURE 2 | Increase in reactive glial markers following infusion of PBS, myoglobin or HspB5. P301S mice (8 weeks old) were infused with PBS (n = 5), myoglobin
(n = 7), or HspB5 (n = 10) for 4 weeks and the superficial cortex was examined in identical areas as the neuronal analysis for Iba1 expression (pan-microglial marker,
A–D) or GFAP (reactive astrocytes, F–I). The dotted boxes in panels (A–D,F–I) have zoomed in inserts as marked by the addition of a ‘i’ to their respective panels,
i.e., (Ai) is the boxed area from (A). Quantification of the ratio of glial markers (E,J), with the asterisks *, signifying P < 0.01 in a one Way ANOVA, Tukey test. All
scale bars are shown for grouped images therefore panels (A–Ii) the scale is the same with a representative bar shown in (A,F) = 200 µm, (Ai,Fi) = 50 µm.
tissue-tec. Cryosections were cut coronally (25 µm), mounted
onto superfrost-plus glass slides (VWR International, East
Grinstead, United Kingdom) and stored at −80◦C. Sections
were blocked in 3% serum solution (goat, sheep or horse serum
chosen depending on secondary antibodies to be used) in a 0.2%
triton-X PBS solution for 1 h before being removed and primary
antibodies added (Table 1) in a 0.2% triton-X PBS solution
containing 1% of the appropriate serum for blocking. After
Frontiers in Neuroscience | www.frontiersin.org 4 June 2020 | Volume 14 | Article 574
fnins-14-00574 June 9, 2020 Time: 20:58 # 5
Hampton et al. HspB5 Is Neuroprotective in Tauopathy
FIGURE 3 | Neuroprotective astrocyte responses to HspB5 depend on concomitant exposure to soluble factors from HspB5-activated microglia. Cultured human
adult astrocytes were exposed to different stimuli including HspB5 alone or in the context of microglia-conditioned media, and transcript levels of LIF (A), NGF (B),
BDNF (C), and EAAT2 (D) were determined after 4 and 24 h. In a separate set of experiments, EAAT2 protein expression on cultured human astrocytes was
examined by immunocytochemical staining at various points in time after stimulation with HspB5 either alone or in the context of microglia-conditioned medium (E),
scale bar = 10 µm for all image panels. In parallel, EAAT2-encoding transcripts were again quantified by RT-PCR (F) ∗P < 0.01.Lower panels (G–N) illustrate in vivo
(Continued)
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FIGURE 3 | Continued
expression of GLT-1 by GFAP+ astrocytes following intracerebral infusion of P301S mice with PBS (n = 5), myoglobin (n = 7), or HspB5 (n = 10).
The white arrows highlight examples of GFAP+ and GLT1+ co-labeling with panel (O) providing quantification of this expression, with differences evaluated by
two-way ANOVA, Tukey, *P < 0.05; **P < 0.01. (P–R,T–V) Are representative images from C57/Bl6 mice also infused with either PBS (n = 3), myoglobin (n = 4),
or HspB5 (n = 5) and again panel (S) provides quantitation of this expression, with differences evaluated by two-way ANOVA, Tukey, *P < 0.05; **P < 0.01.
All scale bars are shown for grouped images therefore panels (G–N,P–V) the scale is the same with a representative bar shown in (G,P) respectively, scale
bar = 50 µm.
TABLE 1 | Antibodies.
Catalog # Antigen/target Source Species generated Dilution
Primary Antibodies
MAB377 NeuN-biotinylated Millipore Bioscience Mouse monoclonal 1:400
A2052 GABA Sigma-Aldrich Rabbit polyclonal 1:500
ab5076 IBA1 Abcam Goat polyclonal 1:150
C9205 GFAP-Cy3 conjugated Sigma-Aldrich Mouse monoclonal 1:400
GLT11-A GLT-1 Alpha-Diagnostic International Rabbit polyclonal 1:200
MCA839 PLP Ab D serotec Mouse monoclonal 1:500
14-9956-82 HLA-DR (LN3) e-bioscience Mouse monoclonal 1:500
MON-RTU1113 GFAP Monosan Mouse monoclonal 1:50
− PTX3 In house Rabbit 1:1000
GA524 GFAP Dako Rabbit polyclonal 1:3000
011-27991 Iba-1 Wako Rabbit polyclonal 1:10000
Secondary Antibodies
SK11021-2 Envision DAKO Goat Ready to use
A-11005 IgG-594 Invitrogen Goat anti mouse 1:250
A-11008 IgG-488 Invitrogen Goat anti rabbit 1:250
4030-04 AP Southern biotech Goat anti rabbit 1:250
S11226 Streptavidin – 568 Molecular probes/Invitrogen – 1:1000
A-11034 IgG Alexa-488 Molecular probes/Invitrogen Goat anti rabbit 1:1000
A-11055 IgG Alexa-488 Molecular probes/Invitrogen Donkey anti goat 1:1000
washing in PBS, secondary antibodies (Table 1) were applied.
Slides were washed in PBS and mounted using Fluorsave reagent
(Calbiochem, Nottingham, United Kingdom). These methods
have been detailed previously (Hampton et al., 2004, 2007, 2010;
Torvell et al., 2019).
Analysis of Neurons and Glia From
in vivo Experiments
Axiovision 4.8 (Zeiss microsystem, Cambridge,
United Kingdom) was used to collect images on a Zeiss
Axiovision upright microscope or Apotome system, or Zen 2009
software was used in conjunction with a Zeiss LSMZ10 confocal
microscope. Images were taken as z-stacks and max-projected
prior to analysis. All images within a dataset were captured
and handled identically for quantitative analysis. Zen blue or
Axiovision (Zeiss) or SigmaScan Pro 5.0 (SPSS, Chicago, IL,
United States) software were used for subsequent quantitative
density measurements and cell counts.
For initial verification analysis of 12 weeks old P301S (n = 4)
compared to age-matched C57/BL6 (n = 7) NeuN and GABA
positive cells were counted in a 155 × 155-µm grid throughout
the superficial cortex, using 4 images per animal, with all cellular
counts expressed as mean numbers of cells per 1 mm2 of
tissue (Figure 1E).
For analysis of NeuN (Figure 1) and GFAP (Figure 2)
expression, images were taken throughout the superficial cortex
and converted to grayscale max-projection TIFFs. All images
were then thresholded such that pixels overlying immune-
positive cells had a grayscale value of 68, and all other pixels had
a value of 0. Therefore, an average intensity could be converted
to density measurements by dividing the output by 68, leading to
a scale of 0 (minimum) to 1 (maximum possible reading) being
generated. These thresholded images were then use to generate
a percentage area of the cortex containing a positive antibody
signal, by dividing the number of positive readings by the total
number of potential readings, multiplied by 100. Between 6 and 8
sections per animal were analyzed, from which a mean percentage
area of the cortical layer containing a positive NeuN or GFAP
signal could be calculated. For analysis of GABA+ neurons
(Figure 1) and IbA1+ microglia (Figure 2) cells were counted
in a 155 × 155-µm grid throughout the superficial cortex, using
between 6 and 8 images per animal. To be able to compare
multiple experiments across different times and institutes, each
group of data except GFAP-GLT1 analysis was normalized to
generate a ratio of infused hemisphere to normal contralateral
hemisphere before being unblinded and grouped correctly.
For GFAP+ GLT-1+ double-labeled positive astrocytes
(Figure 2) cells were counted in a 155× 155-µm grid throughout
the superficial cortex, using between 6 and 8 images per animal,
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with all cellular counts being expressed as mean numbers of cells
per 1 mm2 of tissue.
N numbers for the various groups are shown in their
relevant figure legends.
Isolation and Culturing of Human
Microglia, Astrocytes and Macrophages
Human adult microglia and astrocytes were isolated from fresh
post-mortem brain samples as previously described (Dabir et al.,
2004; Björkdahl et al., 2008). Conditioned media was generated
by supplying microglia with fresh culture medium containing
50 µg/mL HspB5 and medium harvested after 24 h. Microglia-
conditioned media was used for astrocyte stimulations at a 1:1
dilution in the astrocyte culture medium. Astrocyte stimulations
with control stimuli were performed by addition of recombinant
human TNF-α, IFN-γ IL-1β or IL-10 (PeproTech Inc), all at
a final concentration of 2 ng/mL. For RT-PCR analyses of
transcripts at 4 or 24 h of stimulation, total cellular RNA
was isolated from astrocytes using TRizol R© according to the
manufacturer’s protocol (Invitrogen, Breda, Netherlands). RNA
was reverse transcribed into cDNA and transcripts levels relative
to β-actin were determined by RT-PCR using SYBR R©green.
The primers used (Biolegio, Nijmegen, Netherlands) were
the following: EAAT-2 forward: TTCCCTGAAAACCTTGTCCA
and reverse: GGTGGTGCAACCAGGACTTT; LIF forward: CC
AACGTGACGGACTTCCC and reverse: TACACGACTATGCG
GTACAGC; BDNF forward: CTACGAGACCAAGTGCAATCC
and reverse: AATCGCCAGCCAATTCTCTTT; NGF forward:
GGCAGACCCGCAACATTACT and reverse: CACCACCGAC
CTCGAAGTC; β-actin forward: GGTCATCACCATTGGCAA
and reverse: ACGTCACACTTCATGATG.
For immunocytochemical staining of EAAT2, human
astrocytes cultured in chamber slides were rinsed with PBS
and fixed for 10 min at room temperature with 4% (w/v)
paraformaldehyde. To permeabilize the cells and block non-
specific protein-protein interactions, astrocytes were incubated
in 1% (w/v) BSA/10% (v/v) normal goat serum/0.3 M glycine
in 0.1% (v/v) Tween in PBS for 1 h. Staining was performed
by incubation of cells overnight at 4◦C with 5 µg/ml rabbit
polyclonal anti-EAAT2 antibody (ab41621, Abcam) diluted in
5% (v/v) normal goat serum. Cells were next washed in PBS and
incubated for 1 h with goat anti-rabbit Alexa fluor-594 (H + L)
(Life Technologies).
Statistics
Graphs were generated using graphing software (Sigma Plot
11) and statistical tests were performed using SigmaStat and
differences analyzed for statistical significance with ANOVA and
Tukey post hoc test and two-tailed Student’s t-test. P-values of less
than 0.05 were considered statistically significant and whenever
applied, all P-values are shown in the respective figure legends.
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